Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors

Barnard, 2013, Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis, Virology, 443, 278, 10.1016/j.virol.2013.05.013 Buchkovich, 1989, The retinoblastoma protein is phosphorylated during specific phases of the cell cycle, Cell, 58, 1097, 10.1016/0092-8674(89)90508-4 Chang, 2009, Cell cycle perturbation in the hepatocytes of HCV core transgenic mice following common bile duct ligation is associated with enhanced p21 expression, J. Med. Virol., 81, 467, 10.1002/jmv.21403 Chellappan, 1991, The E2F transcription factor is a cellular target for the RB protein, Cell, 65, 1053, 10.1016/0092-8674(91)90557-F Chen, 2009, Emerging roles of E2Fs in cancer: an exit from cell cycle control, Nat. Rev. Cancer, 9, 785, 10.1038/nrc2696 Chow, 2010, Role of Cdk4 in lymphocyte function and allergen response, Cell Cycle, 9, 4922, 10.4161/cc.9.24.14209 De Francesco, 2005, Challenges and successes in developing new therapies for hepatitis C, Nature, 436, 953, 10.1038/nature04080 Elowe, 2011, Bub1 and BubR1: at the interface between chromosome attachment and the spindle checkpoint, Mol. Cell. Biol., 31, 3085, 10.1128/MCB.05326-11 Feld, 2005, Mechanism of action of interferon and ribavirin in treatment of hepatitis C, Nature, 436, 967, 10.1038/nature04082 Honda, 2000, Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation, Gastroenterology, 118, 152, 10.1016/S0016-5085(00)70424-0 Ikeda, 2002, Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells, J. Virol., 76, 2997, 10.1128/JVI.76.6.2997-3006.2002 Kato, 1994, Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation, Cell, 79, 487, 10.1016/0092-8674(94)90257-7 Kato, 2003, Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon, Gastroenterology, 125, 1808, 10.1053/j.gastro.2003.09.023 Keeffe, 2007, Future treatment of chronic hepatitis C, Antivir. Ther., 12, 1015, 10.1177/135965350701200715 Khidr, 2006, RB, the conductor that orchestrates life, death and differentiation, Oncogene, 25, 5210, 10.1038/sj.onc.1209612 Knudsen, 1996, Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites, J. Biol. Chem., 271, 8313, 10.1074/jbc.271.14.8313 Knudson, 1971, Mutation and cancer: statistical study of retinoblastoma, Proc. Natl. Acad. Sci. U.S.A., 68, 820, 10.1073/pnas.68.4.820 Krystof, 2010, Cyclin-dependent kinase inhibitors as anticancer drugs, Curr. Drug Targets, 11, 291, 10.2174/138945010790711950 Kwon, 2002, P21 functions to maintain quiescence of p27-deficient hepatocytes, J. Biol. Chem., 277, 41417, 10.1074/jbc.M203388200 Lamarre, 2003, An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus, Nature, 426, 186, 10.1038/nature02099 Lin, 2005, In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061, J. Biol. Chem., 280, 36784, 10.1074/jbc.M506462200 Lupberger, 2011, EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy, Nat. Med., 17, 589, 10.1038/nm.2341 Macartney, 2014, Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure, Antiviral Res., 105c, 112, 10.1016/j.antiviral.2014.02.019 Malumbres, 2009, Cell cycle, CDKs and cancer: a changing paradigm, Nat. Rev. Cancer, 9, 153, 10.1038/nrc2602 Manns, 2012, Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study, Hepatology, 56, 884, 10.1002/hep.25743 Matsushime, 1992, Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins, Cell, 71, 323, 10.1016/0092-8674(92)90360-O Mayhew, 2007, RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis, Gastroenterology, 133, 976, 10.1053/j.gastro.2007.06.025 McClue, 2002, In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine), Int. J. Cancer, 102, 463, 10.1002/ijc.10738 McClue, 2008, Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo, Drug Metab. Dispos., 36, 561, 10.1124/dmd.107.019232 Meijer, 1997, Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5, Eur. J. Biochem., 243, 527, 10.1111/j.1432-1033.1997.t01-2-00527.x Munakata, 2007, Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein, PLoS Pathog., 3, 1335, 10.1371/journal.ppat.0030139 Munakata, 2005, Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase, Proc. Natl. Acad. Sci. U.S.A., 102, 18159, 10.1073/pnas.0505605102 Musgrove, 2011, Cyclin D as a therapeutic target in cancer, Nat. Rev. Cancer, 11, 558, 10.1038/nrc3090 Nakagawa, 2007, Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice, Biochem. Biophys. Res. Commun., 353, 882, 10.1016/j.bbrc.2006.12.117 Nutley, 2005, Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse, Mol. Cancer Ther., 4, 125, 10.1158/1535-7163.125.4.1 Pawlotsky, 2009, Hepatitis: HCV variability, the immune system and resistance to antiviral drugs, Nat. Rev. Gastroenterol. Hepatol., 6, 383, 10.1038/nrgastro.2009.102 Poordad, 2013, Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection – a randomized trial, Gastroenterology, 145, 10.1053/j.gastro.2013.07.051 Rane, 1999, Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia, Nat. Genet., 22, 44, 10.1038/8751 Reed, 2010, Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control, J. Biol. Chem., 285, 1089, 10.1074/jbc.M109.043380 Sarrazin, 2007, Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir, Gastroenterology, 132, 1767, 10.1053/j.gastro.2007.02.037 Scholle, 2004, Virus-host cell interactions during hepatitis C virus RNA replication: impact of polyprotein expression on the cellular transcriptome and cell cycle association with viral RNA synthesis, J. Virol., 78, 1513, 10.1128/JVI.78.3.1513-1524.2004 Simanis, 1986, The cell cycle control gene cdc2+ of fission yeast encodes a protein kinase potentially regulated by phosphorylation, Cell, 45, 261, 10.1016/0092-8674(86)90390-9 Simmonds, 2005, Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes, Hepatology, 42, 962, 10.1002/hep.20819 Takeuchi, 1999, Real-time detection system for quantification of hepatitis C virus genome, Gastroenterology, 116, 636, 10.1016/S0016-5085(99)70185-X Tateno, 2004, Near completely humanized liver in mice shows human-type metabolic responses to drugs, Am. J. Pathol., 165, 901, 10.1016/S0002-9440(10)63352-4 Teramoto, 1999, Expression of cyclin D2 and D3 in lymphoid lesions, Int. J. Cancer, 81, 543, 10.1002/(SICI)1097-0215(19990517)81:4<543::AID-IJC7>3.0.CO;2-3 Toyoshima, 1994, P27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21, Cell, 78, 67, 10.1016/0092-8674(94)90573-8 Uhlmann, 2011, A quantitative model for cyclin-dependent kinase control of the cell cycle: revisited, Philos. Trans. R. Soc. Lond. B Biol. Sci., 366, 3572, 10.1098/rstb.2011.0082 Wakita, 2005, Production of infectious hepatitis C virus in tissue culture from a cloned viral genome, Nat. Med., 11, 791, 10.1038/nm1268 Waters, 2006, New therapeutic options for hepatitis C, Curr. Opin. Infect. Dis., 19, 615, 10.1097/QCO.0b013e328010a869 Whittaker, 2004, The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway, Cancer Res., 64, 262, 10.1158/0008-5472.CAN-03-0110 Yao, 2003, HCV core/gC1qR interaction arrests T cell cycle progression through stabilization of the cell cycle inhibitor p27Kip1, Virology, 314, 271, 10.1016/S0042-6822(03)00419-7